Frederick Cope, Ph.D., most recently served as assistant director for research and head of program research development for Ohio State University's Comprehensive Cancer Center, the James Cancer Hospital, and the Richard J. Solove Research Institute.
Neoprobe's proprietary radioactive tracing agent, Lymphoseek, is being developed for use with intraoperative lymphatic mapping (ILM). The agent is currently in a phase III, multicenter clinical trial for patients with breast cancer or melanoma, Neoprobe said.
Neoprobe completes financing, December 8, 2008
Neoprobe gets OK for Lymphoseek study, April 16, 2008
Neoprobe announces phase II Lymphoseek results, March 13, 2008
Neoprobe nets financing, December 27, 2007
Neoprobe extends agreement with Ethicon, December 20, 2007
Copyright © 2009 AuntMinnie.com